QGEN Qiagen NV

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and soil samples: 

• The TissueLyser III, a high-throughput instrument for enhanced and versatile disruption of a range of biological samples containing nucleic acids (DNA and RNA).
• The RNeasy PowerMax Soil Pro Kit, designed for isolating high-purity RNA from challenging soil samples rich in PCR inhibitors using QIAGEN’s advanced Inhibitor Removal Technology. 

“The introduction of the TissueLyser III and the RNeasy PowerMax Soil Pro Kit are further milestones in QIAGEN continuing to enhance our best-in-class sample technologies portfolio. These two products are designed to better serve the unique needs of researchers working with difficult samples and enable a higher level of efficiency and accuracy in their work,” said Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN.

The TissueLyser III is a well-suited choice for laboratories seeking efficient sample disruption and high‑quality DNA and RNA purification, even from difficult-to-lyse samples such as bones or tissues. It ensures representative and reproducible results across various research fields, including microbiome, environmental and human biomedical research, forensic analysis and cancer research.

Building on the trusted technology of its prior-generation instrument, which has been cited in over 14,000 scientific publications, the TissueLyser III offers enhanced capabilities for efficient sample disruption – a critical aspect of nucleic acid purification procedures. It provides a convenient, secure process for up to 192 samples as well as large samples of up to 50 mL [1]. Featuring a touchscreen and rotary knob, the TissueLyser III ensures ease of use through seven pre-programmed, as well as five customizable protocols and program cycles.

The TissueLyser III can be used to disrupt biological samples – such as animal and plant tissues, bacteria and yeast – through high-speed shaking in tubes or 96-well plates with stainless zirconium, ceramic, stainless steel or glass beads.

The launch of TissueLyser III demonstrates QIAGEN’s steadfast commitment to consistently enhancing its automated solutions for sample preparation and analysis. It complements the QIAGEN portfolio of high-throughput instruments, which include QIAcube HT, QIAxcel Connect and QIAsymphony.

The TissueLyser III is compatible with many QIAGEN kits – including the new RNeasy PowerMax Soil Pro Kit. This kit is specifically designed for challenging soil samples, particularly those rich in PCR inhibitors such as compost, sediment, and manure. Equipped with larger 50 mL bead-beating tubes, it can handle soil samples of up to 15 grams.

Using QIAGEN’s advanced patent-pending Inhibitor Removal Technology (IRT) and efficient bead beating and lysis chemistry, the kit delivers high-yield, high-purity RNA ready for downstream applications such as real-time quantitative RT-PCR, digital PCR and next-generation sequencing. Compared to its predecessor, the RNeasy PowerSoil Total RNA Kit, the streamlined workflow of the new kit reduces processing time by 60%, enabling faster discoveries and advancements in the understanding of microbial ecosystems.

More information on the TissueLyser III is available here: https://www.qiagen.com/TLIII

More information on the RNeasy PowerMax Soil Pro Kit is available here:https://www.qiagen.com/de/products/discovery-and-translational-research/dna-rna-purification/rna-purification/microbial-rna/rneasy-powermax-soil-pro-kit

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2023, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.Category: Corporate

[1] Available in Q1 2024.

John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com

Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com

Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com

Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com